Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Allergy Therapeutics enrols 250 for grass pollen allergy trial

The dose-setting trial for the vaccine, GrassMATAMPL, will involve 250 patients.
Allergy Therapeutics enrols 250 for grass pollen allergy trial
Allergy said the product design allows for an effective cumulative dose to be attained in up to six weeks

Hay fever vaccine specialist Allergy Therapeutics (LON:AGY) has enrolled 250 patients into a Phase IIb study in the US for a new injectable treatment for grass pollen sufferers.

The dose-setting trial for the vaccine, GrassMATAMPL, will involve 250 patients with headline data expected at the end of the first half of 2016. The results of that should lead on to a US Phase III study.

Allergy said the product design allows for an effective cumulative dose to be attained in up to six weeks, avoiding the continuous administration required by conventional subcutaneous injectable treatments.

For the first time, the dosing study will use two mobile environmental exposure chambers.

Based in Cincinnati and in New Jersey Shore, the chambers are inflatable laboratories that enable subjects to be exposed to a constant concentration of pollen for periods of three hours over four consecutive days. These labs will allow the study to be conducted outside of the grass pollen season.

Tim Higenbottam, Allergy‘s R&D director said the trial was on schedule and would prepare the ground for entry into the high value US market.

“GrassMATAMPL has the potential to become the best in class ultra-short course SCIT [injectable] in the US market”

PhilW.jpg
Why Invest In Allergy Therapeutics plc? Read More Here

Register here to be notified of future AGY Company articles
View full AGY profile

Allergy Therapeutics plc Timeline

Newswire
October 10 2016

Related Articles

Pills and the EU stars
July 19 2016
Alliance's swoop for Sinclair Healthcare Products in December helped it rack up first-half sales of £46.4mln
immupharma-_kiss_pic_with_mum.png
March 01 2016
Lupuzor is not the only part of the Immupharma story and McCarthy plans also to raise the profile of the rest of the group's early stage pipeline in 2016.....
shutterstock_234586750.jpg
October 24 2016
“The positive results from this feasibility award may lead to other opportunities to secure additional funding awards to advance the programme further," Dr John Reader, Sareum's chief scientific officer said.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.